Expertise in
17
conditions

Dr. Bing Xia

Hematology
USC Norris Comprehensive Cancer Center And Hospital
1441 Eastlake Ave, 
Los Angeles, CA 
Expertise in
17
conditions
USC Norris Comprehensive Cancer Center And Hospital
1441 Eastlake Ave, 
Los Angeles, CA 

Overview

Bing Xia is a Hematologist practicing medicine in Los Angeles, California.

Dr. Xia is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and EGFR Positive Lung Cancer.

She is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

USC Norris Comprehensive Cancer Center and Hospital
1441 Eastlake Ave, Los Angeles, CA 90089

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Biological, Other
Study Drugs: Anetumab Ravtansine, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Terminated
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Vopratelimab, Ipilimumab
Study Phase: Phase 2
A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer
A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 13, 2018
Intervention Type: Other, Genetic
View 6 Less Clinical Trials

96 Total Publications

Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis.
Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis.
Journal: Frontiers in immunology
Published: February 26, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (5.5 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
27
conditions
Dr. Andrew Hendifar
Hematology
Expertise in
27
conditions
Dr. Andrew Hendifar
Hematology

Samuel Oschin Cancer Center

127 S San Vicente Blvd # 7, 
Los Angeles, CA 
 (9.6 miles away)
310-423-8030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Hendifar is a Hematologist practicing medicine in Los Angeles, California. Dr. Hendifar is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
27
conditions
Dr. Jorge Nieva
Hematology
Expertise in
27
conditions
Dr. Jorge Nieva
Hematology

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (0.1 miles away)
323-865-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jorge Nieva is a Hematologist practicing medicine in Los Angeles, California. Dr. Nieva is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Gastrostomy.

Frequently Asked Questions about Dr. Bing Xia

How do I make an appointment with Dr. Bing Xia?

You can book an appointment with Dr. Bing Xia by calling their office at 323-865-3105. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bing Xia a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bing Xia is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bing Xia specialize in?

While Dr. Bing Xia is a Hematology, they have specific expertise in Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Bing Xia participate in research or clinical trials?

Yes. Dr. Bing Xia has published 96 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Bing Xia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bing Xia accept my insurance?

Dr. Bing Xia accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 323-865-3105 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Xia's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile